Illustrates the problem of doing a trial where "trial level of care" exceeds "normal level of care" - wound healing is another example, as is a control arm with something like warfarin that is often dosed sub-optimally.
Clearly the drug "works" at some level but may well not be viable in today's environment unless they have a subsequent successful trial - greater convenience simply isn't enough to enable brand-level pricing any more. There is also the GSK competitor to deal with. Likely a bust I think.
Are you guys adding to XNPT under $4? How much of a loss is the failed Parkinson's drug trial?
You can sell the Mar 12 $4 puts for around 55 cents now, which is a 14% return for 3 1/2 months or you are put the stock at 3.45. I am thinking of doing this next week.
They have $2.91/share in cash. Although my guess is that they will burn that rather quickly if their sales for Horizant doesn't pick up soon.
Market Data 
Markets 
AI
